FDA Oral Contraceptives Labeling Guidance Removes Mention Of Emergency Use
This article was originally published in The Pink Sheet Daily
First draft of guidance listed dosing regimens appropriate for emergency use; PhRMA questioned inclusion of the information in earlier comments.
You may also be interested in...
Johnson & Johnson is concerned that the draft guidance will not "objectively relate the risks" to physicians. The company also recommends including newer references for risk information.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.